(HealthDay News) — Younger age at diagnosis of type 2 diabetes is significantly associated with a higher risk for subsequent dementia, according to a study published online in PLOS ONE.
Tolvaptan efficacy was assessed among younger adults 18-35 years with autosomal dominant polycystic kidney disease (ADPKD), who are at high risk for progression.